
Research and development of gene therapy medicines for the treatment of rare diseases.
B
CSR Analysis score
The organization is among the top 20% of most committed organizations, excluding the top 5%, among comparable organizations.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: October 2025
This analysis is not yet available in English. Please see the French version.
Leading organizations
Orphan Europe
B
Development and commercialization of drugs for rare diseases.
Amgen France
B
Research, development, and manufacturing of innovative therapies for serious diseases using biotechnology.
Novartis France
B
Research and development of innovative medicines to improve and extend people's lives.
Initiatives identified among leaders
Création d'un environnement de travail favorable
“Amgen s.a.s. crée un environnement de travail favo...” - Amgen FranceLutter contre le changement climatique
“Orphan Europe prend des mesures pour réduire son i...” - Orphan EuropeMise en place d'un programme de coaching pour aider les jeunes à valoriser leur expérience
“Amgen s.a.s. met en place un programme de coaching...” - Amgen France54% of similar organizations communicate on CSR issues
+1304 initiatives collected from 100 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports